

26 May 2022

**Diaceutics PLC**  
 ("Diaceutics" or "the Company")

**Results of Annual General Meeting**

Diaceutics PLC (AIM: DXRX), the diagnostic commercialisation company, is pleased to announce that all resolutions proposed at its Annual General Meeting held earlier today, were duly passed by a show of hands.

The proxy votes received from shareholders in respect of each resolution are set out below and are available on the Company's website, [www.diaceutics.com](http://www.diaceutics.com).

Resolution	For (excluding at Chair's discretion)		Against		Total votes cast	Withheld
	Number of votes	%	Number of votes	%		
1 Ordinary resolution to receive and consider the 2021 Financial Statements	62,700,675	100.00%	0	0.00%	62,700,675	Nil
2 Ordinary resolution to approve the directors' remuneration report	62,693,325	99.99%	7,350	0.01%	62,700,675	Nil
3 Ordinary resolution to re-elect Nick Roberts as a director	62,700,675	100.00%	0	0.00%	62,700,675	Nil
4 Ordinary resolution to re-elect Charles Hindson as a director	61,651,904	98.32%	900,000	1.44%	62,551,904	Nil
5 Ordinary resolution to re-appoint PricewaterhouseCoopers LLP as auditors	62,550,243	99.75%	1,661	0.01%	62,551,904	Nil
6 Ordinary resolution to authorise the directors to determine the remuneration of the auditors	62,700,675	100.00%	0	0.00%	62,700,675	Nil
7 Ordinary resolution to authorise the directors to allot shares	62,699,175	100.00%	0	0.00%	62,700,675	1,500
8 Special resolution to authorise the directors to disapply pre-emption rights	62,697,164	99.9%	2,011	0.01%	62,699,175	1,500
9 Special resolution to authorise the directors to purchase own shares	60,606,084	99.99%	8,661	0.01%	62,614,745	2,085,930

**Enquiries:**

**Diaceutics PLC**

Peter Keeling, Chief Executive Officer  
 Nick Roberts, Chief Financial Officer

Via Alma PR

**Stifel Nicolaus Europe Limited (Nomad & Broker)**

Ben Maddison, Stewart Wallace, Nick Adams

Tel: +44 (0)20 7710 7600

**Alma PR**

Caroline Forde, Kieran Breheny, Matthew Young

Tel: +44(0)20 3405 0205

diaceutics@almapr.co.uk

**About Diaceutics**

At Diaceutics we believe that every patient should have access to the right treatment at the right time. We provide the world's leading pharmaceutical companies with an end-to-end solution for the launch of precision medicine diagnostics enabled by DXRX - The Diagnostic Network®.

DXRX is the world's first diagnostic commercialisation platform for precision medicine, integrating multiple pipelines of real-world diagnostic testing data from a global network of laboratories.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@lseg.com](mailto:rns@lseg.com) or visit [www.rns.com](http://www.rns.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

RAGKZGZKFVKGZZM